Patrick Kee, MD, PhD, a cardiologist at Vital Heart & Vein, who was not involved in the study, noted the following about the studys results: The investigators demonstrated that the therapeutic efficacy of semaglutide on the primary cardiovascular composite endpoint indeed emerged early and persisted over the initial three months (hazard ratio [HR] 0.63, 95% confidence interval [CI] 0.41-0.95) and the subsequent six months (HR 0.60, 95% CI 0.44-0.81). While the underlying mechanisms of semaglutides early clinical benefits remain under investigation, these findings suggest an encouraging intervention capable of altering the trajectory of [patients with obesity] with established cardiovascular disease but without a diagnosis of diabetes, he told Medical News Today
Lillys Mounjaro, whose main ingredient is tirzepatide, was approved by the FDA in 2022 to treat diabetes, though it has also been used for weight loss
Store unopened pens in the refrigerator between 2C and 8C until the expiry date
17 Sermo member for Family Medicine highlighted, Patients report fewer and less severe side effects with tirzepatide compared to semaglutide, making it a preferred option for some
